Brainsway

About:

Brainsway's patented breakthrough technology launches a new era in brain disorder treatment.

Website: http://www.brainsway.com

Twitter/X: Brainsway

Top Investors: Valor Equity Partners, Phoenix Financial, IBI Investment House, Cybele Holdings, Yelin Lapidot Investment House

Description:

Brainsway's patented breakthrough technology launches a new era in brain disorder treatment. A non-invasive, yet highly effective solution, Brainsway can make a difference in the wellbeing and health of millions of patients worldwide. Brainsway's technology releases millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. Brainsway's treatment was approved by the FDA for Major Depressive Disorder patients*. The technology is also safe, with no systemic effects or long-term side effects, and highly convenient, requiring only brief daily sessions over a couple of weeks. Brainsway's technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials performed. Brainsway technology is based on a patent registered by the U.S. National Institutes of Health (NIH). Brainsway is dedicated to research and continuously explores treatments for a variety of brain disorders.

Total Funding Amount:

$85.5M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Jerusalem, Yerushalayim, Israel

Founded Date:

2003-01-01

Contact Email:

info(AT)brainsway.com

Founders:

Avner Hagai, Avraham Zangen, David Zacut, Yiftach Roth

Number of Employees:

51-100

Last Funding Date:

2024-09-30

IPO Status:

Public

Industries:

© 2025 bioDAO.ai